Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM NASDAQ:CGTX NASDAQ:PMCB NASDAQ:SLXN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$2.54-2.3%$4.47$2.33▼$36.00$7.04M0.9864,661 shs36,956 shsCGTXCognition Therapeutics$1.54-29.0%$1.45$0.22▼$3.83$159.55M1.297.36 million shs13.90 million shsPMCBNuvilex$1.03-1.0%$0.99$0.80▼$2.42$7.07M-0.24150,877 shs80,930 shsSLXNSilexion Therapeutics$3.61-11.3%$9.00$3.55▼$140.74$2.98M0.05983,911 shs523,736 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech-2.31%-1.93%-4.15%-75.62%-91.44%CGTXCognition Therapeutics-29.03%-35.83%0.00%+450.00%+156.62%PMCBNuvilex-0.96%-8.85%+16.12%-2.83%-45.79%SLXNSilexion Therapeutics-11.30%-49.15%-50.34%-70.13%-97.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$2.54-2.3%$4.47$2.33▼$36.00$7.04M0.9864,661 shs36,956 shsCGTXCognition Therapeutics$1.54-29.0%$1.45$0.22▼$3.83$159.55M1.297.36 million shs13.90 million shsPMCBNuvilex$1.03-1.0%$0.99$0.80▼$2.42$7.07M-0.24150,877 shs80,930 shsSLXNSilexion Therapeutics$3.61-11.3%$9.00$3.55▼$140.74$2.98M0.05983,911 shs523,736 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech-2.31%-1.93%-4.15%-75.62%-91.44%CGTXCognition Therapeutics-29.03%-35.83%0.00%+450.00%+156.62%PMCBNuvilex-0.96%-8.85%+16.12%-2.83%-45.79%SLXNSilexion Therapeutics-11.30%-49.15%-50.34%-70.13%-97.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.50Strong Buy$275.0010,726.77% UpsideCGTXCognition Therapeutics 3.25Buy$2.8383.98% UpsidePMCBNuvilex 0.00N/AN/AN/ASLXNSilexion Therapeutics 3.00Buy$75.001,977.56% UpsideCurrent Analyst Ratings BreakdownLatest SLXN, CGTX, AIM, and PMCB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025AIMAIM ImmunoTechMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/8/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.006/26/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$121K56.87N/AN/A$0.20 per share12.70CGTXCognition TherapeuticsN/AN/AN/AN/A$0.31 per shareN/APMCBNuvilexN/AN/AN/AN/A$7.56 per shareN/ASLXNSilexion TherapeuticsN/AN/AN/AN/A($37.31) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.68N/AN/AN/A-12,594.21%-421.73%-147.54%N/ACGTXCognition Therapeutics-$33.97M-$0.67N/AN/AN/AN/A-251.23%-130.75%11/12/2025 (Estimated)PMCBNuvilex$30.66M$2.590.40∞N/AN/A4.60%3.76%N/ASLXNSilexion Therapeutics-$16.44MN/A0.00∞N/AN/AN/A-355.74%N/ALatest SLXN, CGTX, AIM, and PMCB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/15/2025Q1 2026PMCBNuvilexN/A-$0.09N/A-$1.23N/AN/A8/12/2025Q2 2025SLXNSilexion Therapeutics-$3.15-$4.32-$1.17-$4.32N/AN/A8/8/2025Q4 2025PMCBNuvilexN/A-$0.25N/A-$2.02N/AN/A8/7/2025Q2 2025CGTXCognition Therapeutics-$0.12-$0.11+$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/APMCBNuvilexN/AN/AN/AN/AN/ASLXNSilexion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75CGTXCognition TherapeuticsN/A1.541.54PMCBNuvilexN/A7.687.68SLXNSilexion Therapeutics26.582.442.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%CGTXCognition Therapeutics43.35%PMCBNuvilex34.24%SLXNSilexion Therapeutics10.95%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%CGTXCognition Therapeutics14.40%PMCBNuvilex10.20%SLXNSilexion Therapeutics6.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech202.71 million68.74 millionNot OptionableCGTXCognition Therapeutics2073.52 million62.94 millionNot OptionablePMCBNuvilex46.80 million6.10 millionOptionableSLXNSilexion TherapeuticsN/A730,000688,000N/ASLXN, CGTX, AIM, and PMCB HeadlinesRecent News About These CompaniesSilexion Therapeutics Converts Debt to Equity for Nasdaq ComplianceSeptember 15 at 5:10 PM | tipranks.comSilexion Therapeutics prices 1.5M shares at $4.00 in public offeringSeptember 11, 2025 | msn.comSilexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer DataSeptember 11, 2025 | benzinga.comSilexion Therapeutics Announces Pricing of $6.0 Million Public OfferingSeptember 11, 2025 | globenewswire.comSilexion stock soars 400% after positive pancreatic cancer drug dataSeptember 11, 2025 | uk.investing.comSilexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic AdministrationSeptember 11, 2025 | markets.businessinsider.comSilexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic AdministrationSeptember 11, 2025 | globenewswire.comSilexion Therapeutics selects AMS as CRO for SIL204 Phase 2/3 trialsSeptember 4, 2025 | msn.comSilexion Therapeutics Selects AMS Advanced Medical Services as CRO to Support SIL204 Phase 2/3 Clinical Trials Following Promising Preclinical ResultsSeptember 4, 2025 | quiverquant.comQSilexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204September 4, 2025 | globenewswire.comSilexion Therapeutics Corp. to Present at 27th Annual H.C. Wainwright Global Investment ConferenceSeptember 2, 2025 | quiverquant.comQSilexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment ConferenceSeptember 2, 2025 | globenewswire.comSilexion Therapeutics Executes Reverse Stock SplitAugust 22, 2025 | msn.comSilexion Therapeutics Increases Authorized Share CapitalAugust 19, 2025 | tipranks.comSilexion Therapeutics Corp: Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 13, 2025 | finanznachrichten.deSilexion Therapeutics Corp. Reports Second Quarter 2025 Financial Results and Preclinical Advancements in RNAi Therapies for KRAS-Driven CancersAugust 12, 2025 | quiverquant.comQSilexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | globenewswire.comSilexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross ProceedsJuly 31, 2025 | globenewswire.comSilexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS MutationJuly 31, 2025 | globenewswire.comSilexion Therapeutics Holds Annual General MeetingJuly 17, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Is It Too Late to Jump on the Nuclear Bandwagon? By Jordan Chussler | August 25, 2025Advanced Micro Devices' 2026 Forecasts Are Way Too LowBy Thomas Hughes | September 5, 2025Beyond DIY: Home Depot's Conquest of the Professional MarketBy Jeffrey Neal Johnson | September 10, 2025SLXN, CGTX, AIM, and PMCB Company DescriptionsAIM ImmunoTech NYSE:AIM$2.54 -0.06 (-2.31%) Closing price 09/15/2025 03:58 PM EasternExtended Trading$2.56 +0.02 (+0.59%) As of 09/15/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Cognition Therapeutics NASDAQ:CGTX$1.54 -0.63 (-29.03%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.59 +0.05 (+2.99%) As of 09/15/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Nuvilex NASDAQ:PMCB$1.03 -0.01 (-0.96%) Closing price 09/15/2025 03:33 PM EasternExtended Trading$1.03 0.00 (0.00%) As of 09/15/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.Silexion Therapeutics NASDAQ:SLXN$3.61 -0.46 (-11.30%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$3.66 +0.05 (+1.39%) As of 09/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
